China Shineway Pharmaceutical's (HKG:2877) attributable profit fell 13% to 840.1 million yuan in 2024 from 969.5 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.
Earnings per share at the traditional Chinese medicine manufacturer fell to 1.11 yuan from 1.28 yuan in the previous year.
Revenue declined 16% to 3.78 billion yuan from 4.52 billion yuan a year earlier.
The company declared its first interim dividend of 0.36 yuan per share, payable May 20 to shareholders on record as of May 7.
Shares plunged 8% during Friday's afternoon trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。